DLK1: A novel target for immunotherapeutic remodeling of the tumor blood vasculature

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1958-1968

  Chi Sabins, Nina ^a   Taylor, Jennifer L ^a   Fabian, Kellsye Pl ^a   Appleman, Leonard J ^a,b   Maranchie, Jodi K ^a,b   Stolz, Donna Beer ^a   Storkus, Walter J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD31 ANTIGEN; CD8 ANTIGEN; DLK1 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA SECRETASE INHIBITOR; HERMES ANTIGEN; HISTONE DEMETHYLASE; LENTIVIRUS VECTOR; N [N (3,5 DIFLUOROPHENACETYL LEVO ALANYL)] PHENYLGLYCINE TERT BUTYL ESTER; NOTCH RECEPTOR; PROTEIN JARID1B; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PERICYTE; PREVALENCE; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM;

LENTIVIRUS; MURINAE; MUS;

ANIMALS; APOPTOSIS; CANCER VACCINES; CAPILLARY PERMEABILITY; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL HYPOXIA; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PERICYTES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; VACCINES, SUBUNIT;

EID: 84885019870     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.133     Document Type: Article

References (50)

1. Gerhardt, H and Semb, H (2008). Pericytes: gatekeepers in tumour cell metastasis? J Mol Med 86: 135-144.
2. Morikawa, S, Baluk, P, Kaidoh, T, Haskell, A, Jain, RK and McDonald, DM (2002). Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000.
3. Gaengel, K, Genove, G, Armulik, A and Betsholtz, C (2009). Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29: 630-638.
4. Fukumura, D, Duda, DG, Munn, LL and Jain, RK (2010). Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17: 206-225.
5. Finke, JH, Tubbs, R, Connelly, B, Pontes, E and Montie, J (1988). Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci 532: 387-394.
6. Muul, LM, Spiess, PJ, Director, EP and Rosenberg, SA (1987). Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989-995.
7. Lokich, J (1997). Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 20: 416-418.
8. Motzer, RJ and Bukowski, RM (2006). Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608.
9. Escudier, B, Roigas, J, Gillessen, S, Harmenberg, U, Srinivas, S, Mulder, SF et al. (2009). Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4068-4075.
10. Najjar, YG and Rini, BI (2012). Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol 4: 183-194.
11. Helfrich, I, Scheffrahn, I, Bartling, S, Weis, J, von Felbert, V, Middleton, M et al. (2010). Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207: 491-503.
12. Vujanovic, L and Butterfield, LH (2007). Melanoma cancer vaccines and anti-tumor T cell responses. J Cell Biochem 102: 301-310.
13. Ahmed, F, Steele, JC, Herbert, JM, Steven, NM and Bicknell, R (2008). Tumor stroma as a target in cancer. Curr Cancer Drug Targets 8: 447-453.
14. Zhao, X, Bose, A, Komita, H, Taylor, JL, Chi, N, Lowe, DB et al. (2012). Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 188: 1782-1788.
15. Komita, H, Zhao, X, Taylor, JL, Sparvero, LJ, Amoscato, AA, Alber, S et al. (2008). CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res 68: 8076-8084.
16. Huang, YH, Lin, YH, Chi, HC, Liao, CH, Liao, CJ, Wu, SM et al. (2013). Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. Cancer Res 73: 2505-2517.
17. Jain, RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
18. Hamzah, J, Jugold, M, Kiessling, F, Rigby, P, Manzur, M, Marti, HH et al. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
19. Ranganathan, P, Weaver, KL and Capobianco, AJ (2011). Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11: 338-351.
20. Falix, FA, Aronson, DC, Lamers, WH and Gaemers, IC (2012). Possible roles of DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta 1822: 988-995.
21. Begum, A, Kim, Y, Lin, Q and Yun, Z (2012). DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo. Cancer Lett 318: 26-33.
22. Murphy, GP and Hrushesky, WJ (1973). A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013-1025.
23. Stallcup, WB (2002). The NG2 proteoglycan: past insights and future prospects. J Neurocytol 31: 423-435.
24. Zhao, X, Bose, A, Komita, H, Taylor, JL, Kawabe, M, Chi, N et al. (2011). Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumorassociated stromal antigens. Mol Ther 19: 805-814.
25. Sasaki, K, Zhu, X, Vasquez, C, Nishimura, F, Dusak, JE, Huang, J et al. (2007). Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 67: 6451-6458.
26. Bose, A, Taylor, JL, Alber, S, Watkins, SC, Garcia, JA, Rini, BI et al. (2011). Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129: 2158-2170.
27. He, Y, Zhang, J, Donahue, C and Falo, LD Jr (2006). Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24: 643-656.
28. Matsumoto, S, Yasui, H, Batra, S, Kinoshita, Y, Bernardo, M, Munasinghe, JP et al. (2009). Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc Natl Acad Sci USA 106: 17898-17903.
29. Wilson, WR and Hay, MP (2011). Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
30. Cabarcas, SM, Mathews, LA and Farrar, WL (2011). The cancer stem cell niche-there goes the neighborhood? Int J Cancer 129: 2315-2327.
31. Levesque, JP, Winkler, IG, Hendy, J, Williams, B, Helwani, F, Barbier, V et al. (2007). Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxiainducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 25: 1954-1965.
32. Roesch, A, Fukunaga-Kalabis, M, Schmidt, EC, Zabierowski, SE, Brafford, PA, Vultur, A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
33. Liang, D, Ma, Y, Liu, J, Trope, CG, Holm, R, Nesland, JM et al. (2012). The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12: 201.
34. Mathieu, J, Zhang, Z, Zhou, W, Wang, AJ, Heddleston, JM, Pinna, CM et al. (2011). HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-4652.
35. Lobry, C, Oh, P and Aifantis, I (2011). Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 208: 1931-1935.
36. Saha, B, Jyothi Prasanna, S, Chandrasekar, B and Nandi, D (2010). Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50: 1-14.
37. Mizuno, T, Nagao, M, Yamada, Y, Narikiyo, M, Ueno, M, Miyagishi, M et al. (2006). Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 13: 131-140.
38. Keith, B, Johnson, RS and Simon, MC (2012). HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
39. Reis, M, Czupalla, CJ, Ziegler, N, Devraj, K, Zinke, J, Seidel, S et al. (2012). Endothelial Wnt/s-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 209: 1611-1627.
40. Ueno, K, Hirata, H, Hinoda, Y and Dahiya, R (2013). Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer 132: 1731-1740.
41. Wang, Y and Sul, HS (2006). Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol 26: 5421-5435.
42. Zhang, J, Fukuhara, S, Sako, K, Takenouchi, T, Kitani, H, Kume, T et al. (2011). Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin. J Biol Chem 286: 8055-8066.
43. Perez-Cabezas, B, Naranjo-Gomez, M, Bastos-Amador, P, Requena-Fernandez, G, Pujol-Borrell, R and Borras, FE (2011). Ligation of Notch receptors in human conventional and plasmacytoid dendritic cells differentially regulates cytokine and chemokine secretion and modulates Th cell polarization. J Immunol 186: 7006-7015.
44. Rini, BI and Atkins, MB (2009). Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
45. Faivre, S, Demetri, G, Sargent, W and Raymond, E (2007). Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745.
46. Finke, JH, Rini, B, Ireland, J, Rayman, P, Richmond, A, Golshayan, A et al. (2008). Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682.
47. Ozao-Choy, J, Ma, G, Kao, J, Wang, GX, Meseck, M, Sung, M et al. (2009). The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69: 2514-2522.
48. Trevino-Villarreal, JH, Cotanche, DA, Sepulveda, R, Bortoni, ME, Manneberg, O, Udagawa, T et al. (2011). Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma. J Histochem Cytochem 59: 1060-1075.
49. Crisan, M, Corselli, M, Chen, WC and Peault, B (2012). Perivascular cells for regenerative medicine. J Cell Mol Med 16: 2851-2860.
50. Klungsoyr, L and Stoa, KF (1954). Spectrophotometric determination of hemoglobin oxygen saturation: the method of Drabkin & Schmidt as modified for its use in clinical routine analysis. Scand J Clin Lab Invest 6: 270-276.